Abstract
OBJECTIVE
Peptide YY₃₋₃₆ (PYY₃₋₃₆), a Y2 receptor agonist, and oxyntomodulin, a glucagon-like peptide 1 (GLP-1) receptor agonist, are cosecreted by intestinal L-cells after each meal. Separately each hormone acts as an endogenous satiety signal and reduces appetite in humans when infused intravenously. The aim of the current study was to investigate whether the anorectic effects of PYY3-36 and oxyntomodulin can be additive.
RESEARCH DESIGN AND METHODS
Twelve overweight or obese human volunteers underwent a randomized, double-blinded, placebo-controlled study. Art ad libitum test meal was used to measure energy intake during intravenous infusions of either PYY₃₋₃₆ or oxyntomodulin or combined PYY₃₋₃₆/oxyntomodulin.
RESULTS
Energy intake during coadministration of PYY₃₋₃₆ and oxyntomodulin was reduced by 42.7% in comparison with the saline control and was significantly lower than that during infusions of either hormone alone.
CONCLUSIONS
The anorectic effects of PYY₃₋₃₆ and oxyntomodulin can be additive in overweight and obese humans. Coadministration of Y2 receptor agonists and GLP-1 receptor agonists may be a useful treatment strategy for obesity.